Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

RIBAVIRIN 200 MG CAPSULE

Ribavirin
$1.2755per EA

Strength

200 mg/1

Manufacturer

Aurobindo Pharma Limited

NDC

65862029042

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Last Updated

6/15/2016

Active Ingredients

RIBAVIRIN

Approval Type

Generic (ANDA)

FDA Application

ANDA079117

On Market Since

9/17/2009

Pharmacological Classes

Nucleoside Analog Antiviral
Nucleoside Analog

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

+73.4%

Generic Alternatives

Save up to 47%

1 alternative • Same active ingredient

RIBAVIRIN 200 MG TABLET
Generic
65862020768•Aurobindo Pharma Limited
$0.6754
Save 47%

Related Drugs

Same classification

ACYCLOVIR 200 MG/5 ML SUSP
Generic
00472008216•Actavis Pharma, Inc.
$0.0739
per ML
ACYCLOVIR 200 MG/5 ML SUSP
Generic
31722068147•Camber Pharmaceuticals Inc.
$0.0739
per ML
ACYCLOVIR 200 MG/5 ML SUSP
Generic
62135080347•Chartwell RX LLC
$0.0739
per ML
ACYCLOVIR 200 MG/5 ML SUSP
Generic
70954018810•ANI Pharmaceuticals, Inc.
$0.0739
per ML
ACYCLOVIR 200 MG/5 ML SUSP
Generic
72205017072•Novadoz Pharmaceuticals LLC
$0.0739
per ML
ACYCLOVIR 200 MG/5 ML SUSP
Generic
72888007917•Advagen Pharma Ltd.
$0.0739
per ML
ACYCLOVIR 400 MG TABLET
Generic
75834012201•Nivagen Pharmaceuticals Inc.
$0.0779
per EA
ACYCLOVIR 400 MG TABLET
Generic
75834012205•Nivagen Pharmaceuticals Inc.
$0.0779
per EA
ACYCLOVIR 200 MG CAPSULE
Generic
75834012401•Nivagen Pharmaceuticals Inc.
$0.0971
per EA
ACYCLOVIR 400 MG TABLET
Generic
00904750761•Major Pharmaceuticals
$0.0980
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy